Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Anika Therapeutics Inc. (ANIK : NSDQ)

• Company Description    Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. Number of Employees: 288

• Price / Volume Information    Yesterday's Closing Price: $11.78 Daily Weekly Monthly 20 Day Moving Average: 110,684 shares Shares Outstanding: 14.34 (millions) Market Capitalization: $168.94 (millions) Beta: 0.64 52 Week High: $29.12 52 Week Low: $10.47 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.53% 0.61% 12 Week -15.98% -29.33% Year To Date -28.43% -32.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 32 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-457-9000 fax: 781-305-9720 investorrelations@anika.com http://www.anika.com

• General Corporate Information    Officers Cheryl R. Blanchard - Chief Executive Officer and President John B. Henneman - Chairman Stephen Griffin - Executive Vice President; Chief Financial Officer Ian McLeod - Vice President; Chief Accounting Officer Joseph H. Capper - Director Peer Information Anika Therapeutics Inc. (CORR.) Anika Therapeutics Inc. (RSPI) Anika Therapeutics Inc. (CGXP) Anika Therapeutics Inc. (BGEN) Anika Therapeutics Inc. (GTBP) Anika Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 035255108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 14.34 Most Recent Split Date: (:1) Beta: 0.64 Market Capitalization: $168.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 10.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.14 Price/Cash Flow: 123.50 Price / Sales: 1.23 EPS Growth vs. Year Ago Period: -411.11% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: -35.42% vs. Previous Quarter: -14.49% ROE 06/30/25 - - 03/31/25 - -7.22 12/31/24 - -3.88 ROA 06/30/25 - - 03/31/25 - -5.64 12/31/24 - -3.04 Current Ratio 06/30/25 - - 03/31/25 - 5.73 12/31/24 - 4.88 Quick Ratio 06/30/25 - - 03/31/25 - 4.53 12/31/24 - 3.85 Operating Margin 06/30/25 - - 03/31/25 - -9.10 12/31/24 - -4.81 Net Margin 06/30/25 - - 03/31/25 - -41.28 12/31/24 - -37.15 Pre-Tax Margin 06/30/25 - - 03/31/25 - -3.43 12/31/24 - -2.31 Book Value 06/30/25 - - 03/31/25 - 10.35 12/31/24 - 10.51 Inventory Turnover 06/30/25 - - 03/31/25 - 1.33 12/31/24 - 1.07 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©